Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol

A. M. Carella, P. Carlier, A. Congiu, D. Occhini, S. Nati, G. Santini, D. Pierluigi, D. Giordano, A. Bacigalupo, E. Damasio

Research output: Contribution to journalArticle

Abstract

Fifteen patients with very poor prognosis Hodgkin's disease in remission after MOPP/ABVD regimen, were treated with high-dose chemotherapy (HDC) and autologous marrow transplantation (ABMT) immediately after achieving complete remission (CR). Thirteen patients (86.6%) remain alive in unmaintained CR at a median time of 36 months (range 10-64 months) post-transplant. In the other two patients reasons for failure included relapse of Hodgkin's disease (one patient) and death due to interstitial pneumonitis secondary to carmustine therapy. These patients were compared with a historical control group consisting of 24 patients with the same poor prognostic factors, who achieved CR with MOPP/ABVD and did not receive other treatment. Eight out of 24 patients (33%) remain alive and well in unmaintained CR at a median time of 42 months (range 19-83 months). The administration of MOPP/ABVD combined with HDC and ABMT was not associated with an increased incidence of major toxicity. The results achieved support the early sequential treatment of a highly effective drug combination followed by HDC/ABMT that can substantially improve the likelihood of cure in these advanced stage very poor prognosis Hodgkin's disease patients.

Original languageEnglish
Pages (from-to)99-103
Number of pages5
JournalBone Marrow Transplantation
Volume8
Issue number2
Publication statusPublished - 1991

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Carella, A. M., Carlier, P., Congiu, A., Occhini, D., Nati, S., Santini, G., Pierluigi, D., Giordano, D., Bacigalupo, A., & Damasio, E. (1991). Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplantation, 8(2), 99-103.